Evidence map›Paper›PMID 38445456›Full record

ArticleClinical and translational medicine2024

Distinct fibroblast subpopulations associated with bone, brain or intrapulmonary metastasis in advanced non-small-cell lung cancer.

Ke Xu, Hao Wang, Yu-Xia Zou, Huan-Huan Zhang, Yue-Nan Wang, Xue-Ru Ren, Han-Qi Wang, Ye-Hong Xu, Jia-Jun Li, Hao Tang and 12 more

Open access · goldAbstract read
In one paragraph

Article in Clinical and translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. COL3A1NPJ precision oncology · 2026
    Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 2 institutions in 1 country.

Ke XuDepartment of Respiratory Oncology, Division of Life Sciences and Medicine, the First Affiliated Hospital of University of USTC, University of Science and Technology of China, Hefei, Anhui, China.ORCID 0009-0005-0381-6317
Hao WangDepartment of Respiratory Oncology, Division of Life Sciences and Medicine, the First Affiliated Hospital of University of USTC, University of Science and Technology of China, Hefei, Anhui, China.
Yu-Xia ZouDepartment of Respiratory Oncology, Division of Life Sciences and Medicine, the First Affiliated Hospital of University of USTC, University of Science and Technology of China, Hefei, Anhui, China.
Huan-Huan ZhangDepartment of Respiratory Oncology, Division of Life Sciences and Medicine, the First Affiliated Hospital of University of USTC, University of Science and Technology of China, Hefei, Anhui, China.
Yue-Nan WangDepartment of Respiratory Oncology, Division of Life Sciences and Medicine, the First Affiliated Hospital of University of USTC, University of Science and Technology of China, Hefei, Anhui, China.
Xue-Ru RenDepartment of Respiratory Oncology, Division of Life Sciences and Medicine, the First Affiliated Hospital of University of USTC, University of Science and Technology of China, Hefei, Anhui, China.
Han-Qi WangDepartment of Respiratory Oncology, Division of Life Sciences and Medicine, the First Affiliated Hospital of University of USTC, University of Science and Technology of China, Hefei, Anhui, China.
Ye-Hong XuDepartment of Respiratory Oncology, Division of Life Sciences and Medicine, the First Affiliated Hospital of University of USTC, University of Science and Technology of China, Hefei, Anhui, China.
Jia-Jun LiDepartment of Respiratory Oncology, Division of Life Sciences and Medicine, the First Affiliated Hospital of University of USTC, University of Science and Technology of China, Hefei, Anhui, China.
Hao TangDepartment of Respiratory Oncology, Division of Life Sciences and Medicine, the First Affiliated Hospital of University of USTC, University of Science and Technology of China, Hefei, Anhui, China.
Cheng HeDepartment of Respiratory Oncology, Division of Life Sciences and Medicine, the First Affiliated Hospital of University of USTC, University of Science and Technology of China, Hefei, Anhui, China.
Song WeiDepartment of Respiratory Oncology, Division of Life Sciences and Medicine, the First Affiliated Hospital of University of USTC, University of Science and Technology of China, Hefei, Anhui, China.
Tian TianDepartment of Respiratory Oncology, Division of Life Sciences and Medicine, the First Affiliated Hospital of University of USTC, University of Science and Technology of China, Hefei, Anhui, China.
Lai-Lin LiDepartment of Respiratory Oncology, Division of Life Sciences and Medicine, the First Affiliated Hospital of University of USTC, University of Science and Technology of China, Hefei, Anhui, China.
Hui ZhouDepartment of Respiratory Oncology, Division of Life Sciences and Medicine, the First Affiliated Hospital of University of USTC, University of Science and Technology of China, Hefei, Anhui, China.
Lin-Juan XuDepartment of Respiratory Oncology, Division of Life Sciences and Medicine, the First Affiliated Hospital of University of USTC, University of Science and Technology of China, Hefei, Anhui, China.
Jing-Wen FangDepartment of Oncology, Division of Life Sciences and Medicine, the First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, Anhui, China.
Chuang GuoDepartment of Oncology, Division of Life Sciences and Medicine, the First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, Anhui, China.
Jia-Xuan YangHanGene Biotech, Xiaoshan Innovation Polis, Hangzhou, China.
You-Yang ZhouHanGene Biotech, Xiaoshan Innovation Polis, Hangzhou, China.
Zhi-Hong ZhangDepartment of Respiratory Oncology, Division of Life Sciences and Medicine, the First Affiliated Hospital of University of USTC, University of Science and Technology of China, Hefei, Anhui, China.ORCID 0009-0007-8290-9208
Yue-Yin PanDepartment of Oncology, Division of Life Sciences and Medicine, the First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, Anhui, China.
University of Science and Technology of China · CNThe First People's Hospital of Xiaoshan District, Hangzhou · CN

Funding

National Nature Science Foundation of China 82172775Naturel Science Foundation of Anhui Province 1908085MH260Subproject of National Science and Technology Major Project 2020ZX09201-004
6 · The paper itself

Abstract

backgroundBone or brain metastases may develop in 20-40% of individuals with late-stage non-small-cell lung cancer (NSCLC), resulting in a median overall survival of only 4-6 months. However, the primary lung cancer tissue's distinctions between bone, brain and intrapulmonary metastases of NSCLC at the single-cell level have not been underexplored.

methodsWe conducted a comprehensive analysis of 14 tissue biopsy samples obtained from treatment-naïve advanced NSCLC patients with bone (n = 4), brain (n = 6) or intrapulmonary (n = 4) metastasis using single-cell sequencing originating from the lungs. Following quality control and the removal of doublets, a total of 80 084 cells were successfully captured.

resultsThe most significant inter-group differences were observed in the fraction and function of fibroblasts. We identified three distinct cancer-associated fibroblast (CAF) subpopulations: myofibroblastic CAF (myCAF), inflammatory CAF (iCAF) and antigen-presenting CAF (apCAF). Notably, apCAF was prevalent in NSCLC with bone metastasis, while iCAF dominated in NSCLC with brain metastasis. Intercellular signalling network analysis revealed that apCAF may play a role in bone metastasis by activating signalling pathways associated with cancer stemness, such as SPP1-CD44 and SPP1-PTGER4. Conversely, iCAF was found to promote brain metastasis by activating invasion and metastasis-related molecules, such as MET hepatocyte growth factor. Furthermore, the interaction between CAFs and tumour cells influenced T-cell exhaustion and signalling pathways within the tumour microenvironment.

conclusionsThis study unveils the direct interplay between tumour cells and CAFs in NSCLC with bone or brain metastasis and identifies potential therapeutic targets for inhibiting metastasis by disrupting these critical cell-cell interactions.

Indexed as

Brain NeoplasmsCarcinoma, Non-Small-Cell LungLung NeoplasmsBrainFibroblastsHumansTumor MicroenvironmentCAFfibroblastnon-small-cell lung cancersingle-cell RNA-seqtumour microenvironment

Identifiers

PMID38445456
PMCPMC10915739
OpenAlexW4392499631

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.